ENTO Entero Therapeutics Inc.

Subscribe to $ENTO

Entero Therapeutics Inc.

Subscribe to $ENTO

$ENTO

Biotechnology: Pharmaceutical Preparations

Health Care

IPO Year: 2016

Exchange: NASDAQ

Recent Analyst Ratings for Entero Therapeutics Inc.

Date	Price Target	Rating	Analyst

See more ratings

Entero Therapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Uppal Manpreet
3 - Entero Therapeutics, Inc. (0001604191) (Issuer)
2/13/25 5:02:13 PM ET
$ENTO
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form 3 filed by new insider Corbett Eric
3 - Entero Therapeutics, Inc. (0001604191) (Issuer)
2/13/25 5:00:59 PM ET
$ENTO
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form 3 filed by new insider Paolone Richard
3 - Entero Therapeutics, Inc. (0001604191) (Issuer)
2/13/25 4:59:40 PM ET
$ENTO
Biotechnology: Pharmaceutical Preparations
Health Care
Chief Financial Officer Romano Sarah sold $465 worth of shares (727 units at $0.64), decreasing direct ownership by 4% to 17,287 units (SEC Form 4)
4 - Entero Therapeutics, Inc. (0001604191) (Issuer)
1/8/25 4:23:52 PM ET
$ENTO
Biotechnology: Pharmaceutical Preparations
Health Care
Chief Financial Officer Romano Sarah sold $212 worth of shares (476 units at $0.45), decreasing direct ownership by 3% to 18,014 units (SEC Form 4)
4 - Entero Therapeutics, Inc. (0001604191) (Issuer)
10/10/24 5:00:12 PM ET
$ENTO
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form 3 filed by new insider Ramdeen Timothy R.
3 - Entero Therapeutics, Inc. (0001604191) (Issuer)
8/14/24 9:46:33 PM ET
$ENTO
Biotechnology: Pharmaceutical Preparations
Health Care
Chief Financial Officer Romano Sarah sold $664 worth of shares (621 units at $1.07), decreasing direct ownership by 3% to 18,490 units (SEC Form 4)
4 - Entero Therapeutics, Inc. (0001604191) (Issuer)
7/3/24 2:34:36 PM ET
$ENTO
Biotechnology: Pharmaceutical Preparations
Health Care
Chairman and CEO Sapirstein James sold $1,379 worth of shares (1,289 units at $1.07), decreasing direct ownership by 3% to 35,816 units (SEC Form 4)
4 - Entero Therapeutics, Inc. (0001604191) (Issuer)
7/3/24 2:33:15 PM ET
$ENTO
Biotechnology: Pharmaceutical Preparations
Health Care
Director Khosla Chaitan Phd was granted 24,889 shares (SEC Form 4)
4 - Entero Therapeutics, Inc. (0001604191) (Issuer)
6/12/24 6:23:05 PM ET
$ENTO
Biotechnology: Pharmaceutical Preparations
Health Care

Entero Therapeutics Inc.

Recent Analyst Ratings for Entero Therapeutics Inc.

Entero Therapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Uppal Manpreet

SEC Form 3 filed by new insider Corbett Eric

SEC Form 3 filed by new insider Paolone Richard

Chief Financial Officer Romano Sarah sold $465 worth of shares (727 units at $0.64), decreasing direct ownership by 4% to 17,287 units (SEC Form 4)

Chief Financial Officer Romano Sarah sold $212 worth of shares (476 units at $0.45), decreasing direct ownership by 3% to 18,014 units (SEC Form 4)

SEC Form 3 filed by new insider Ramdeen Timothy R.

Chief Financial Officer Romano Sarah sold $664 worth of shares (621 units at $1.07), decreasing direct ownership by 3% to 18,490 units (SEC Form 4)

Chairman and CEO Sapirstein James sold $1,379 worth of shares (1,289 units at $1.07), decreasing direct ownership by 3% to 35,816 units (SEC Form 4)

Director Khosla Chaitan Phd was granted 24,889 shares (SEC Form 4)